Long-COVID in children and adolescents: a systematic review and meta-analyses.

Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. · 2022

Read Long-COVID in children and adolescents: a systematic review and meta-analyses. by Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9226045.txt.

Introduction

Lopez-Leon and co-authors systematically review long COVID in children and adolescents and pool the results. Most long COVID research had focused on adults. The team searched for studies of patients aged 0 to 18 with at least 30 cases each. Studies had to meet a standard national definition of the condition.

They included 21 studies with 80,071 children and adolescents in all. Pooled prevalence of long COVID was 25.24%. Mood symptoms were most common at 16.50%, then fatigue at 9.66% and sleep disorders at 8.42%. Infected children faced higher risk of lasting breathlessness, loss of smell or taste, and fever than controls. The authors note weak definitions and high variation across studies.

Catalog record

CREATORLopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9226045

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Long-COVID in children and adolescents: a systematic review and meta-analyses By Sandra Lopez-Leon, Talia Wegman-Ostrosky, Norma Cipatli Ayuzo del Valle, Carol Perelman, Rosalinda Sepulveda, Paulina A Rebolledo, Angelica Cuapio, Sonia Villapol Published in: Scientific Reports DOI: 10.1038/s41598-022-13495-5 ABSTRACT Abstract The objective of this systematic review and meta-analyses is to estimate the prevalence of long-COVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥ 12 weeks) symptoms. Random-effects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity. Subject terms: Paediatrics, Public health, Immunopathogenesis, Infection, Inflammation INTRODUCTION It has been over 2 years since the coronavirus disease 2019 (COVID-19) pandemic was first declared. Consequently, millions of cases and thousands of deaths have been reported worldwide1. Still, treatments have been developed during this time, and effective vaccines have been widely administered to the population, both children and adults, protecting millions from severe disease and death2. Until now, the focus was primarily aimed at the acute phase of the disease. However, many individuals experience debilitating COVID-19 symptoms months later, requiring additional medical attention and follow-up. Severe COVID-19 is less common in children than in adults3; however, at least two long-term consequences occur following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children: multisystem inflammatory syndrome (MIS-C) and long-COVID. Both consequences can even appear in asymptomatic patients4. MIS-C is a condition where different body parts become inflamed4, it occurs in less than 0.01% of children infected and requires intensive care support in 68% of cases5. Long-COVID is a heterogeneous multisystemic condition for which there is still no precise definition and includes signs and symptoms that persist, develop, or fluctuate after SARS-CoV-2 infection. In October 2021, the WHO proposed a clinical definition for post-COVID-19 through a Delphi consensus stating it generally occurs three months from the onset of COVID-19, with symptoms lasting at least two months and cannot be explained by an alternative diagnosis6. On February 2nd, 2022, the National Institute for Health and Care Excellence (NICE) published a guideline defining long-COVID as signs and symptoms that continue or develop after acute COVID‑19. This includes ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post‑COVID-19 syndrome (12 weeks or more)7. Other organizations, such as the National Institutes of Health (N.I.H.), also define long-COVID as post-acute symptoms after 4 weeks8. Many authors have used the following terms interchangeably when referring to long-COVID: long-haulers, COVID-long, post-acute sequelae of COVID-19 (PASC), post-COVID, COVID syndrome, and long-COVID. In the present study, we will use the generic definition from NICE and N.I.H., referring to long-COVID. To date, most of the published research on long-COVID primarily focuses on adult populations, and there is limited information on pediatric populations9,10. The most recent meta-analysis has studied the long-COVID symptoms and their prevalence, risk factors, type, and duration, including studies up to July 2021, encompassing 23,141 children and young people9. The most common symptoms were fatigue 47%, dyspnea 43%, and headache 35%. In addition, compared to controls, the prevalence of cognitive difficulties, headache, loss of smell, sore throat, and sore eyes was statistically higher9. However, due to the lack of data, this study could only compute the pooled prevalence for 10 symptoms. To date, the potential range of signs and symptoms and their frequency of occurrence in children and adolescents remains unclear11. There is a need to create awareness among parents, physicians, and researchers on the afflictions following COVID-19 infection and the health system to better understand the sequelae to provide targeted medical attention and treatment. This systematic review and meta-analyses aim to estimate the prevalence of long-COVID in children and adolescents and identify the full spectrum of symptoms. METHODS Data sources and search strategy This systematic review and meta-analyses were reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline12. It examines the prevalence of long-COVID signs and symptoms in children under the age of 18 with a diagnosed case of COVID-19 (confirmed via real-time reverse transcription-polymerase chain reaction (rt-PCR), antigen or antibody (or serology tests). To achieve this, two independent investigators (T.W.O. and S.L.L.) searched PubMed and Embase to identify studies that met the following criteria: (1) a minimum of 30 patients, (2) ages ranged from 0 to 18 years, (3) studies published in English, (4) published before February 10th, 2022, and (5) meet the NICE definition of long-COVID, (6) excluding cohorts of children composed of exclusively pre-existing chronic diseases, or exclusively of MIS-C in children, and (7) excluding references of editorials, reviews, and commentaries (Fig. 1). [Figure: PRISMA diagram with exclusion criteria. Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) screening process flow. Out of 8373 identified studies and after applying the inclusion and exclusion criteria, 21 studies were included in the quantitative synthesis.] The search terms used to identify publications discussing long-COVID in children were: (COVID-19 OR COVID OR SARSCOV-2 OR coronavirus OR “long-COVID” OR “post COVID”) AND (PASC OR haulers OR lingering OR “post-acute” OR persistent OR convalescent OR convalescence OR sequelae OR post-viral) AND (pediatric OR kids OR young OR infant OR children OR adolescents). Given that MedLine was included in the PubMed search, we excluded articles from MedLine in the Embase search along with those not related to COVID-19. Observational studies, including cohorts and cross-sectional studies, were analyzed only when the cases (numerator) were part of a COVID-19 cohort (denominator). Titles, abstracts, and full texts of articles were independently screened. Disagreement on including a full-text article was discussed among all the authors. We developed and registered a review protocol (PROSPERO registration number: CRD42021275408). Screening and data extraction Data were extracted by four authors (A.C., N.C.A., P.R., R.S.) and Quality-Controlled (QCed) data by two authors (T.W.O., N.C.P.). Discrepancies were discussed with a third author. The descriptive variables extracted were country, study design, period of study, collection mode, follow-up time, the severity of COVID-19, sample size, COVID-19 diagnosis, age, percentage of males, outcomes, and names used to describe the long-term effects of COVID-19. Statistical analysis Random-effects meta-analyses were performed for symptoms reported in two or more studies using MetaXL software to estimate the pooled prevalence, which uses a double arcsine transformation13. Prevalence (presented as percentages) with 95% confidence intervals (C.I.s) was estimated. Numerators represented the

Read the complete text